WO2003104277A3 - Gene d'activation de stat6 - Google Patents

Gene d'activation de stat6

Info

Publication number
WO2003104277A3
WO2003104277A3 PCT/JP2003/007123 JP0307123W WO03104277A3 WO 2003104277 A3 WO2003104277 A3 WO 2003104277A3 JP 0307123 W JP0307123 W JP 0307123W WO 03104277 A3 WO03104277 A3 WO 03104277A3
Authority
WO
WIPO (PCT)
Prior art keywords
stat6
activation
proteins
dna
recombinant vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2003/007123
Other languages
English (en)
Other versions
WO2003104277A2 (fr
Inventor
Toshinori Sugahara
Akio Matsuda
Goichi Honda
Shuji Muramatsu
Kenya Ishizawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Pharma Corp
Original Assignee
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corp filed Critical Asahi Kasei Pharma Corp
Priority to AU2003241182A priority Critical patent/AU2003241182A1/en
Publication of WO2003104277A2 publication Critical patent/WO2003104277A2/fr
Publication of WO2003104277A3 publication Critical patent/WO2003104277A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des protéines dont l'activité favorise l'activation de STAT6 et qui sont utilisées pour diagnostiquer, traiter ou prévenir des maladies associées à une activation excessive ou à une inhibition de STAT6. De l'ADN complémentaire codant une protéine pouvant favoriser l'activation de STAT6 a été cloné au moyen d'un plasmide rapporteur de réponse STAT6, à partir d'une bibliothèque d'ADN complémentaire construite à l'aide de fibroblastes pulmonaires humains et d'éléments analogues, et la séquence d'ADN ainsi que la séquence d'acides aminés qui en découle sont déterminées. L'invention se rapporte en outre à un procédé de criblage d'une substance destinée à inhiber ou favoriser l'activation de STAT6, au moyen des protéines selon l'invention, de l'ADN codant ces protéines, d'un vecteur recombinant contenant cet ADN ainsi que d'un transformant qui comporte ce vecteur recombinant.
PCT/JP2003/007123 2002-01-22 2003-06-05 Gene d'activation de stat6 Ceased WO2003104277A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003241182A AU2003241182A1 (en) 2002-06-05 2003-06-05 Stat6 activation gene

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
JPNO.2002-164257 2002-06-05
JP2002164257 2002-06-05
US38591202P 2002-06-06 2002-06-06
US60/385,912 2002-06-06
JPNO.2002-377326 2002-12-26
JP2002377326 2002-12-26
US43646702P 2002-12-27 2002-12-27
US60/436,467 2002-12-27
JPNO.2003-137505 2003-05-15
JP2003137505 2003-05-15
US47083603P 2003-05-16 2003-05-16
US60/470,836 2003-05-16

Publications (2)

Publication Number Publication Date
WO2003104277A2 WO2003104277A2 (fr) 2003-12-18
WO2003104277A3 true WO2003104277A3 (fr) 2004-07-08

Family

ID=29741172

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/007123 Ceased WO2003104277A2 (fr) 2002-01-22 2003-06-05 Gene d'activation de stat6

Country Status (2)

Country Link
AU (1) AU2003241182A1 (fr)
WO (1) WO2003104277A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2512808A1 (fr) * 2003-01-18 2004-08-12 Marc Elliot Rothenberg Regulation de gene induit par allergene
DE102004026309A1 (de) * 2004-05-26 2005-12-29 Haarlems Allergenen Laboratorium B.V. Pharamzeutische Zusammensetzung zur Behandlung allergischer Erkrankungen, pathologischer Atemswegsveränderungen und von Krebs durch Modulation der Genexpression des Stat6
US20090035312A1 (en) * 2005-09-30 2009-02-05 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
CN110551756A (zh) * 2019-09-12 2019-12-10 宝船生物医药科技(上海)有限公司 一种报告基因细胞株及其构建方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092616A1 (en) * 2001-05-25 2003-05-15 Akio Matsuda STAT6 activation gene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092616A1 (en) * 2001-05-25 2003-05-15 Akio Matsuda STAT6 activation gene

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE SWALLPROT [online] 16 October 2001 (2001-10-16), XP002248865, accession no. EBI Database accession no. Q9NZN4 *
MASUDA AKIO ET AL: "Interleukin-15 prevents mouse mast cell apoptosis through STAT6-mediated Bcl-xL expression.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 28, 13 July 2001 (2001-07-13), pages 26107 - 26113, XP002248864, ISSN: 0021-9258 *
POHL UTE ET AL: "EHD2, EHD3, and EHD4 encode novel members of a highly conserved family of EH domain-containing proteins.", GENOMICS., vol. 63, no. 2, 15 January 2000 (2000-01-15), pages 255 - 262, XP002248862, ISSN: 0888-7543 *
STOLZENBERGER SASCHA ET AL: "Specific inhibition of interleukin-4-dependent Stat6 activation by an intracellularly delivered peptide.", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 268, no. 17, September 2001 (2001-09-01), pages 4809 - 4814, XP002248863, ISSN: 0014-2956 *

Also Published As

Publication number Publication date
WO2003104277A2 (fr) 2003-12-18
AU2003241182A1 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
Hofmann et al. Molecular cloning of a histidine-rich Ca2+-binding protein of sarcoplasmic reticulum that contains highly conserved repeated elements
EP1541686A4 (fr) CONSTRUCTION D'UN ANTICORPS AU MOYEN D'UNE SOURIS MRL/lPR
MA32031B1 (fr) Procedes et compositions faisant appel a des polypeptides de fusion klotho-fgf
WO2004078777A3 (fr) Proteines protegees contre la dipeptidylpeptidase
EA200600746A1 (ru) Конструкции нуклеиновых кислот
ATE358724T1 (de) Expression regulierende sequenzen vom schimmelpilz chrysosporium
CY1110185T1 (el) Τροποποιημενη πρωτεϊνη vp1-καψιδιου του παρβοϊου β19
EA200401531A1 (ru) Новые фосфолипазы и их применение
MXPA02008239A (es) Gen humano de la esquizofrenia.
WO2003104277A3 (fr) Gene d'activation de stat6
EA200400812A1 (ru) Секретируемый белок
MXPA04004561A (es) Distribuidor de aire para sistema de biolixiviacion.
ATE517629T1 (de) Verwendung eines proteins der crmp familie zur behandlung von krankheiten des immunsystems
WO2003076658A3 (fr) Gene de predisposition a la maladie de parkinson idiopathique a apparition tardive
WO1999063094A3 (fr) Sequences nucleotidiques et proteiques gpr1 et methodes y relatives
ATE368121T1 (de) Expressionskassetten zur bidirektionalen transgenen expression von nukleinsäuren in pflanzen
Hook et al. Identification of zymogen and mature forms of human carboxypeptidase HA processing enzyme for the synthesis of peptide hormones
WO2004078112A3 (fr) Gene induisant l'apoptose
WO2004053117A3 (fr) Serine protease
ATE556135T1 (de) Neues protein
DE60122301D1 (de) Kaliumkanalprotein kcnq5, ein ziel für erkrankungen des zentralen nervensystems und herz-gefäss-systems
WO2005030798A3 (fr) Agents inhibiteurs et agents stimulateurs de l'enzyme de conversion du tnf-$g(a)
WO2003080105A3 (fr) Genes regulateurs de l'angiogenese, preparations pharmaceutiques les contenant et leurs applications
AU1214202A (en) Coactivation of nuclear receptors
DE60321443D1 (de) Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP